Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections
Authors:
- Giacomo StroffoliniGSGiacomo Stroffolini
- Amedeo De NicolòANAmedeo De Nicolò
- Alberto GaviraghiAGAlberto Gaviraghi
- Jacopo MulaJMJacopo Mula
- Giuseppe CaritiGCGiuseppe Cariti
- Silvia ScabiniSSSilvia Scabini
- Alessandra MancaAMAlessandra Manca
- Jessica CusatoJessica Cusato
- Silvia CorcioneSilvia Corcione
- Stefano BonoraSBStefano Bonora
- Giovanni Di PerriGPGiovanni Di Perri
- Francesco Giuseppe De RosaFRFrancesco Giuseppe De Rosa
Open Access
- 6 September 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (9) , 1882
Abstract
Dalbavancin (DBV) is a lipoglycopeptide approved for the treatment of Gram-positive infections of the skin and skin-associated structures (ABSSSIs). Currently, its off-label use at different dosages for other infections deserves attention. This work aimed to study the clinical effectiveness and tolerability of DBV in outpatients with ABSSSIs, osteoarticular (OA), or other infections, treated with either one or two 1500 mg doses of dalbavancin, for different scheduled periods. A liquid chromatography–tandem mass spectrometry method was used to measure total DBV concentrations. PK/PD parameters and the clinical and microbiological features of this cohort were evaluated in order to investigate the best predictors of treatment success in real-life settings. Of the 76 screened patients, 41 completed the PK study. Long-term PK was comparable to previous studies and showed significant differences between genders and dosing schedules. Few adverse events were observed, and treatment success was achieved in the vast majority of patients. Failure was associated with lower PK parameters, particularly Cmax. Concluding, we were able to describe DBV PK and predictors of treatment success in selected infections in this cohort, finding DBV Cmax as a possible candidate for therapeutic drug-monitoring purposes, as well as highlighting the dual-dose one-week-apart treatment as the optimal choice for OA infections.Keywords
This publication has 34 references indexed in Scilit:
- Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011–2016)International Journal of Antimicrobial Agents, 2018
- Dalbavancin in the treatment of different gram-positive infections: a real-life experienceInternational Journal of Antimicrobial Agents, 2018
- Area under the curve predictions of dalbavancin, a new lipoglycopeptide agent, using the end of intravenous infusion concentration data point by regression analyses such as linear, log-linear and power modelsXenobiotica, 2017
- Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibioticInfectious Diseases, 2017
- A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure InfectionClinical Infectious Diseases, 2015
- Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancinDiagnostic Microbiology and Infectious Disease, 2015
- Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular TissueAntimicrobial Agents and Chemotherapy, 2015
- Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin InfectionNew England Journal of Medicine, 2014
- Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection modelInternational Journal of Antimicrobial Agents, 2013
- Pharmacokinetics of dalbavancin in plasma and skin blister fluidJournal of Antimicrobial Chemotherapy, 2007